References

1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med . 2020;26(4):450-452.
2. Mulangu S, Dodd LE, Davey Jr RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med . 2019;381(24):2293-2303.
3. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med . 2017;9(396).
4. Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. 2020.
5. Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther . 2020;14(2):73-76. doi:10.5582/ddt.2020.01015
6. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med . 2020.
7. Dorward J, Gbinigie K. Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19. 2020.
8. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet . 2020;395(10238):1695-1704. doi:10.1016/s0140-6736(20)31042-4
9. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering . 2020.
10. Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect . 2020.
11. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv . 2020.
12. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clin Immunol . 2020:108459.
13. Syal K. COVID‐19: herd immunity and convalescent plasma transfer therapy. J Med Virol . 2020.
14. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. 2020.
15. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci . 2020;117(17):9490-9496.
16. Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J Med Virol . 2020.
17. Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med . 2007;357(11):1162-1163.
18. Kumar GV, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect . 2020:100682.
19. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci . 2020;117(20):10970-10975.
20. Sallard E, Lescure F-X, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res . 2020:104791.
21. Huang X, Zhou M-Y, Cheng Y, et al. Opportunities and challenges of traditional Chinese medicine going abroad for COVID-19 treatment.Am J Emerg Med . 2020;(January). doi:10.1016/j.ajem.2020.06.008
22. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci . 2020;16(10):1708.
23. Gao D, Niu M, Wei S, et al. Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection. Front Pharmacol . 2020;11:746.
24. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med . 2020;1(ahead-of-print).
25. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis . 2020:1.
26. Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg . 2020.
27. Cox MJ, Loman N, Bogaert D, O’grady J. Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe . 2020;1(1):e11.
28. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID‐19. Pharmacother J Hum Pharmacol Drug Ther . 2020;40(5):487-488.
29. Conforti C, Giuffrida R, Zalaudek I, Di Meo N. Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak. Dermatol Ther . 2020.
30. Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv . 2020.
31. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents . 2020:105949.
32. Borba M, de Almeida Val F, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb cl. MedRxiv . 2020.
33. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med . 2020:1-2.
34. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ . 2020;192(17):E450-E453.
35. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama . 2020.
36. Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. MedRxiv . 2020:2020.06.22.20137273. doi:10.1101/2020.06.22.20137273
37. Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov . 2020;5:100028.
38. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care . 2020;24(1):1-2.
39. Liu Y, Pang Y, Hu Z, et al. Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis . 2020.
40. Leslie M. T cells found in coronavirus patients ‘bode well’ for long-term immunity. Science (80- ) . 2020;368(6493):809-810. doi:10.1126/science.368.6493.809
41. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England) . 2020;395(10223):e30.
42. Chatterjee S. SGLT-2 inhibitors for COVID-19—A miracle waiting to happen or just another beat around the bush? Prim Care Diabetes . 2020.
43. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report.Immunity . 2020.
44. Mullard A. COVID-19 vaccine development pipeline gears up.Lancet . 2020;395(10239):1751-1752.
45. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: the current state of play. Paediatr Respir Rev . 2020.
46. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients.bioRxiv . 2020.
47. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med . 2020;382(21):1969-1973.